AMENDMENT TO
RESEARCH COLLABORATION AND LICENSE AGREEMENT (U.S.)
This Amendment to the Research Collaboration and License Agreement (U.S.)
is entered into as of this 12th day of June, 1998 by and between Biogen,
Inc., a Massachusetts corporation located at 00 Xxxxxxxxx Xxxxxx, Xxxxxxxxx,
XX 00000 ("Biogen") and CV Therapeutics, Inc., a Delaware corporation with
principal offices located at 0000 Xxxxxx Xxxxx, Xxxx Xxxx, XX 00000 ("CVT").
WHEREAS, Biogen and CVT are parties to a certain Research Collaboration
and License Agreement (U.S.), dated as of March 7, 1997 (the "U.S. Research
Agreement") and Biotech Manufacturing Ltd. ("BML") and CVT are parties to a
certain Loan Agreement dated as of March 7, 1997 (the "Loan Agreement") in
connection therewith; and
WHEREAS, in connection with the amendment to the Loan Agreement, the
parties desire to amend the U.S. Research Agreement to change the definition
of "Performance Assessment Study";
NOW, THEREFORE, in consideration of the premises and mutual covenants
contained in this Amendment, the parties agree as follows:
1. Definitions.
The capitalized terms used in this Amendment shall have the meanings
assigned to such terms in the U.S. Research Agreement.
2. Amended provisions.
Biogen and CVT agree that the U.S. Research Agreement shall be amended
in the manner set forth below:
(a) Section 1.19 of the U.S. Research Agreement is amended to be,
and read, in its entirety as follows:
The term "PHASE II PERFORMANCE ASSESSMENT STUDY" shall mean the
clinical study known as BG1205.
3. Ratification.
Except as otherwise expressly set forth in this Amendment, all of the
terms and conditions of the Loan Agreement shall remain in full force
and effect.
IN WITNESS WHEREOF, the parties have executed this Amendment on the date
first above written.
BIOGEN, INC. CV THERAPEUTICS, INC.
By: /s/ Xxxxx X. Xxxxx By: /s/ Xxxxx X. Xxxxx
Title: Chief Executive Officer Title: Chief Executive Officer
